Aspirin in the treatment and prevention of cardiovascular disease: Past and current perspectives and future directions

American Journal of Medicine

Volumn 126, Issue 5, 2013, Pages 373-378

  Hennekens, Charles H ^a   Dalen, James E ^b  

^a FLORIDA ATLANTIC UNIVERSITY   (United States)

^b UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

Aspirin; Cardiovascular Disease; Prevention; Treatment

Indexed keywords

ACETYLSALICYLIC ACID; PLACEBO; STREPTOKINASE; TISSUE PLASMINOGEN ACTIVATOR;

ACUTE HEART INFARCTION; ACUTE OCCLUSIVE STROKE; ARTHRITIS; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; DRUG MECHANISM; HEALTH CARE COST; HEART INFARCTION; HUMAN; MEDICAL RESEARCH; MORBIDITY; MORTALITY; PATIENT COMPLIANCE; PRIMARY PREVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; SECONDARY PREVENTION; TRANSIENT ISCHEMIC ATTACK;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; CARDIOVASCULAR DISEASES; HUMANS; PRIMARY PREVENTION; RISK ASSESSMENT; SECONDARY PREVENTION;

EID: 84876297828     PISSN: 00029343     EISSN: 15557162     Source Type: Journal    
DOI: 10.1016/j.amjmed.2012.12.013     Document Type: Review

References (40)

1. C.H. Hennekens, J.E. Buring Epidemiology in Medicine 1987 Little, Brown and Company Boston
2. C.H. Hennekens, D. DeMets Statistical association and causation: contributions of different types of evidence JAMA 306 2011 1134 1136
3. C.H. Hennekens, D. DeMets The need for large scale randomized evidence without undue emphasis on small trials, meta-analyses or subgroup analyses JAMA 302 2009 2361 2362
4. A. Williams, C.H. Hennekens The role of aspirin in cardiovascular diseases: forgotten benefits? Exp Opin Pharmacother 5 2004 109 115
5. J.R. Vane Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs Nat New Biol 231 25 1971 232 235
6. L.L. Craven Acetylsalicylic acid: possible preventive of coronary thrombosis Ann West Med Surg 4 1950 95 99
7. Boston Collaborative Drug Surveillance Group Regular aspirin intake and acute myocardial infarction Br Med J 1 1974 440 443
8. H. Jick, O.S. Miettinen Regular aspirin use and myocardial infarction Br Med J 1 1976 1037
9. C.H. Hennekens, L.K. Karlson, B. Rosner A case-control study of regular aspirin use and coronary death Circulation 58 1 1978 35 38
10. E.C. Hammond, L. Garfinkel Aspirin and coronary heart disease: findings of a prospective study Br Med J 2 1975 269 271
11. J.E. Manson, M.J. Stampfer, G.A. Colditz A prospective study of aspirin use and primary prevention of cardiovascular disease in women JAMA 266 1991 521 527
12. Antithrombotic Trialists Collaboration H. Barnett, M.-G. Bousser, G. Boysen et al. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction and stroke in high-risk patients BMJ 324 2002 71 86
13. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group Randomized trial of intravenous streptokinase, oral aspirin, both or neither among 17,187 cases of suspected acute myocardial infarction (Australia: Hunt D; Austria: Dienstl F; Belgium: De Backer G; Canada: Cairns J; Denmark: Pedersen F; Finland: Kala R; France: Boissel J-P; Germany: Schroder R; Ireland: Horgan J; New Zealand: Fitzpatrick M; Norway: Kjekshus Collins R, Peto R, Sleight P; US: Hennekens CH Lancet 2 1988 349 360
14. C.H. Hennekens, M.A. Jonas, J.E. Buring The benefits of aspirin in acute myocardial infarction: still a well-kept secret in the U.S. Arch Intern Med 154 1994 37 39
15. C.H. Hennekens, W.R. Schneider The need for wider and appropriate utilization of statins and aspirin in treatment and prevention of cardiovascular disease Expert Rev Cardiovasc Ther 6 1 2008 95 107
16. International Stroke Trial Collaborative Group The International Stroke Trial (IST): a randomized trial of aspirin, subcutaneous heparin, both, or neither among 19,435 patients with acute ischemic stroke Lancet 349 1997 1569 1581
17. Chinese Acute Stroke Trial (CAST) Collaborative Group CAST: randomized placebo-controlled trial of early aspirin use in 20,000 patients with acute ischemic stroke Lancet 349 1997 1641 1649
18. Steering Committee of the Physicians' Health Study Research Group Preliminary report on the aspirin component of the ongoing Physicians' Health Study N Engl J Med 318 1988 262 264
19. Steering Committee of the Physicians' Health Study Research Group Final report on the aspirin component of the ongoing Physicians' Health Study N Engl J Med 321 1989 129 135
20. Antithrombotic Trialists Collaboration Primary Prevention Writing Group C. Baigent, L. Blackwell, J. Buring et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials Lancet 373 2009 1849 1860
21. P. Rothwell, G.R. Fowkes, J.F.F. Belch, H. Ogawa, C. Warlow, T.W. Meade Effect of daily aspirin on long term risk of death due to cancer: analysis of individual patient data from randomized trials Lancet 377 2011 31 41
22. C.H. Hennekens, D. Hollar, C. Baigent Sex-related differences in response to aspirin in cardiovascular disease: an untested hypothesis Nat Clin Pract Cardiovasc Med 3 1 2006 4 5
23. J.E. Dalen Aspirin for the primary prevention of stroke and myocardial infarction: ineffective or wrong dose? Am J Med 123 2 2009 101 102
24. Bayer HealthCare ARRIVE. Aspirin to Reduce Risk of Initial Vascular Events [online] http://www.arrive-study.com/EN/study.cfm Accessed December 16, 2012
25. M. Nelson, C. Reid, L. Beilin Aspirin in Reducing Events in the Elderly (ASPREE) Study Group Rationale for a trial of low-dose aspirin for the primary prevention of major adverse cardiovascular events and vascular dementia in the elderly. Aspirin in Reducing Events in the Elderly (ASPREE) Drugs Aging 20 2003 897 903
26. University of Oxford ASCEND. A Study of Cardiovascular Events in Diabetes [online] http://www.ctsu.ox.ac.uk/ascend/ Accessed December 16, 2012
27. G. De Berardis, M. Sacco, V. Evangelista ACCEPT-D Study Group Aspirin and Simvastatin Combination for Cardiovascular Events Prevention Trials in Diabetes (ACCEPT-D): design of a randomized study of the efficacy of low-dose aspirin in the prevention of cardiovascular events in subjects with diabetes mellitus treated with statins Trials 8 2007 21
28. C.H. Hennekens, C. Baigent Aspirin in primary prevention-good news and bad news Nat Rev Cardiol 9 2012 262 263
29. J.E. Dalen, C.H. Hennekens, S. Mora Aspirin in the primary prevention of cardiovascular disease Med Roundtable: Gen Med Ed 1 1 2012 59 65
30. H. Schroder Nitric oxide and aspirin: a new mediator for an old drug Am J Ther 16 1 2009 17 23
31. U. Forstermann, T. Munzel Endothelial nitric oxide synthase in vascular disease: from marvel to menace Circulation 113 13 2006 1708 1714
32. N. Grosser, H. Schröder Aspirin protects endothelial cells from oxidant damage via the nitric oxide-cGMP pathway Arterioscler Thromb Vasc Biol 23 8 2003 1345 1351
33. P. O'Kane, L. Xie, Z. Liu Aspirin acetylates nitric oxide synthase type 3 in platelets thereby increasing its activity Cardiovasc Res 83 1 2009 123 130
34. N. Grosser, A. Abate, S. Oberle Heme oxygenase-1 induction may explain the antioxidant profile of aspirin1 Biochem Biophys Res Commun 308 4 2003 956 960
35. T. Malinski, M.W. Radomski, Z. Taha, S. Moncada Direct electrochemical measurement of nitric oxide released from human platelets Biochem Biophys Res Commun 194 2 1993 960 965
36. A.J. Cardounel, H. Cui, A. Samouilov Evidence for the pathophysiological role of endogenous methylarginines in regulation of endothelial NO production and vascular function J Biol Chem 282 2 2007 879 887
37. C.H. Hennekens, W.R. Schneider, A. Pokov A randomized trial of aspirin at clinically relevant doses and nitric oxide formation in humans J Cardiovasc Pharmacol Ther 15 2010 344 348
38. S. Hetzel, D. DeMets, R. Schneider Aspirin increases nitric oxide formation in chronic stable coronary disease J Cardiovasc Pharmacol Ther 2012 in press
39. P.R. Hebert, M.A. Pfeffer, C.H. Hennekens Use of statins and aspirin to reduce cardiovascular disease J Cardiovasc Pharmacol Ther 7 2002 77 80
40. C.H. Hennekens, F. Sacks, A. Tonkin Additive benefits of pravastatin and aspirin to decrease risks of cardiovascular disease: randomized and observational comparisons of secondary prevention trials and their meta-analysis Arch Intern Med 164 2004 40 44